ZIOPHARM, Inc.

78 articles about ZIOPHARM, Inc.

• ZIOPHARM, Inc. Reports First Quarter Financial Results and Highlights

  5/5/2011

• ZIOPHARM, Inc. to Present at the 10th Annual JMP Securities Research Conference

  5/3/2011

• ZIOPHARM, Inc. to Present at the Deutsche Bank Securities 36th Annual Health Care Conference

  4/27/2011

• ZIOPHARM, Inc. to Present at Upcoming Investor Conferences

  3/29/2011

• ZIOPHARM, Inc. to Present at Barclays Capital 2011 Global Healthcare Conference

  3/8/2011

• ZIOPHARM, Inc. and Solasia Pharma K.K. Announce License and Collaboration Agreement for Darinaparsin in Asia

  3/7/2011

• ZIOPHARM, Inc. Announces Full Exercise of Underwriter’s Option; Completion of Public Offering

  2/9/2011

• ZIOPHARM, Inc. ZIOPHARM Prices Public Offering of Common Stock

  2/3/2011

• ZIOPHARM, Inc. Announces Proposed Public Offering of Common Stock

  2/3/2011

• ZIOPHARM, Inc. Receives Positive Opinion for Orphan Drug Designation for Darinaparsin from European Medicines Agency

  1/20/2011

• ZIOPHARM, Inc. and Intrexon Corporation Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics; Intrexon Will Buy 5% of Ziopharm's Stock for About $11.6 Million

  1/7/2011

• ZIOPHARM, Inc. Presents Positive Palifosfamide PICASSO Phase II Results in Oral Session at American Society of Clinical Oncology

  6/8/2010

• ZIOPHARM, Inc. Reports First Quarter Financial Results

  4/30/2010

• ZIOPHARM, Inc. Commences Oral Indibulin Phase I/II Trial in Breast Cancer -- at Memorial Sloan-Kettering Cancer Center

  4/8/2010

• ZIOPHARM, Inc. Elects George B. Abercrombie, former CEO of Hoffmann-La Roche AG, to Board of Directors

  4/6/2010

• ZIOPHARM, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results

  3/18/2010

• ZIOPHARM, Inc. Prices Public Offering

  12/4/2009

• ZIOPHARM, Inc. Reports Third Quarter Financial Results and Updated Clinical Progress

  11/11/2009

• ZIOPHARM, Inc. Reports Second Quarter Financial Results and Updates Clinical Programs

  8/13/2009

• ZIOPHARM, Inc. Presents Positive Indibulin Translational And Dose Scheduling Data At American Society of Clinical Oncology

  6/2/2009